Semaglutide medications like Ozempic and Wegovy have shown proven results for managing conditions like type 2 diabetes and obesity. Also known as GLP-1 agonists, these drugs work by mimicking a ...

GLP-1 RA use was linked to a 2.21-fold risk of developing neovascular age-related macular degeneration// (nAMD) * Only 0.2% ...

A European health authority has found that medications containing semaglutide—such as Ozempic, Wegovy, and Rybelsus—can ...

Researchers have zeroed in on yet another possible ocular concern for diabetes patients who take popular GLP-1 therapies in a ...

Statistical hazard modeling showed a significantly elevated risk of nAMD ... reported with semaglutide. The potential for delayed-onset ocular harm may warrant periodic eye examinations for ...

Canada: A recent observational cohort study from Canada revealed that older diabetic patients taking GLP-1 receptor ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

A new study has found a significant association between the use of GLP-1s such as Ozempic and Wegovy with a higher risk of developing a serious eye condition in patients with diabetes. Here are four t ...

Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...

Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular ...

The European Medicines Agency has identified a rare eye condition risk linked to Novo Nordisk’s semaglutide drugs.

the increased risk was not associated with other eye diseases, nor was it driven by lixisenatide specifically, suggesting a possible class-wide effect, predominantly tied to semaglutide.